Dupixent for cancer? Researchers test blockbuster med as an immunotherapy-booster

Regeneron and Sanofi’s blockbuster Dupixent has conquered numerous anti-inflammatory indications. New research in mice now suggests that the monoclonal antibody could have a future as an immunology booster for lung cancer, too.